MBX Biosciences (MBX) EBIT (2023 - 2026)

MBX Biosciences (MBX) has 4 years of EBIT data on file, last reported at -$27.3 million in Q1 2026.

• For the quarter ending Q1 2026, EBIT fell 2.77% year-over-year to -$27.3 million; the trailing twelve-month figure through Mar 2026 stood at -$98.8 million (down 21.35% YoY), and the FY2025 full-year result was -$98.1 million, down 43.79% from the prior year.
• EBIT declined to -$27.3 million in Q1 2026, from -$25.8 million in the prior quarter.
• In the past five years, EBIT ranged from a high of -$10.0 million in Q4 2023 to a low of -$27.3 million in Q1 2026.
• A 4-year average of -$19.5 million and a median of -$19.6 million in 2024 frame the typical range for EBIT.
• Across the five-year window, EBIT sank 99.26% in 2025 and slipped 2.77% in 2026, its largest moves.
• Tracing MBX's EBIT over 4 years: stood at -$10.0 million in 2023, then sank by 86.27% to -$18.6 million in 2024, then sank by 38.61% to -$25.8 million in 2025, then decreased by 5.7% to -$27.3 million in 2026.
• Business Quant data shows MBX's EBIT at -$27.3 million in Q1 2026, -$25.8 million in Q4 2025, and -$23.9 million in Q3 2025.